ADVM Adverum Biotechnologies
- 6.0100
- +0.2600+4.52%
Adverum Biotechnologies News
Truist Financial Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating
Adverum Biotechnologies Analyst Ratings
H.C. Wainwright Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $30
Buy Rating on Adverum Biotechnologies: Ixo-vec's Promising Potential in Transforming Wet AMD Treatment
Adverum Biotechnologies Is Maintained at Sector Perform by RBC Capital
Adverum Biotechnologies Analyst Ratings
RBC Capital Initiates Adverum Biotechnologies(ADVM.US) With Hold Rating, Announces Target Price $10
TD Cowen Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating
Oppenheimer Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $28
A Quick Look at Today's Ratings for Adverum Biotechnologies(ADVM.US), With a Forecast Between $10 to $30
Buy Rating on Adverum Biotechnologies Driven by Ixo-vec's Promising Data and Potential Impact on AMD Treatment
Adverum Biotechnologies (ADVM) Gets a Buy From TD Cowen
Oppenheimer Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $28
Chardan Capital Upgrades Adverum Biotechnologies(ADVM.US) to Buy Rating
Oppenheimer Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $28
Oppenheimer Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $28
Mizuho Securities Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $20
Oppenheimer Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $28
Analysts Offer Insights on Healthcare Companies: Adverum Biotechnologies (ADVM), Biomea Fusion (BMEA) and Travere Therapeutics (TVTX)
Mizuho Securities Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Announces Target Price $20
Analysis
Price Target
No Data
No Data